DOCSLIB.ORG

Cancer Risk Among Patients with Myotonic Muscular Dystrophy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Risk Among Patients with Myotonic Muscular Dystrophy ORIGINAL CONTRIBUTION Cancer Risk Among Patients With Myotonic Muscular Dystrophy Shahinaz M. Gadalla, MD, PhD Context Myotonic muscular dystrophy (MMD) is an autosomal-dominant multisys- Marie Lund, MD tem neuromuscular disorder characterized by unstable nucleotide repeat expansions. Ruth M. Pfeiffer, PhD Case reports have suggested that MMD patients may be at increased risk of malig- nancy, putative risks that have never been quantified. Sanne Gørtz, MSc Objective To quantitatively evaluate cancer risk in patients with MMD, overall and Christine M. Mueller, DO by sex and age. Richard T. Moxley III, MD Design, Setting, and Participants We identified 1658 patients with an MMD dis- Sigurdur Y. Kristinsson, MD, PhD charge diagnosis in the Swedish Hospital Discharge Register or Danish National Pa- tient Registry between 1977 and 2008. We linked these patients to their correspond- Magnus Bjo¨rkholm, MD, PhD ing cancer registry. Patients were followed up from date of first MMD-related inpatient Fatma M. Shebl, MD, PhD or outpatient contact to first cancer diagnosis, death, emigration, or completion of can- cer registration. James E. Hilbert, MS Main Outcome Measures Risks of all cancers combined and by anatomic site, strati- Ola Landgren, MD, PhD fied by sex and age. Jan Wohlfahrt, DMSc Results One hundred four patients with an inpatient or outpatient discharge diag- Mads Melbye, MD, DMSc nosis of MMD developed cancer during postdischarge follow-up. This corresponds to Mark H. Greene, MD an observed cancer rate of 73.4 per 10 000 person-years in MMD vs an expected rate of 36.9 per 10 000 person-years in the general Swedish and Danish populations com- YOTONIC MUSCULAR DYS- bined (standardized incidence ratio [SIR], 2.0; 95% CI, 1.6-2.4). Specifically, we ob- trophy (MMD) is an au- served significant excess risks of cancers of the endometrium (n=11; observed rate, tosomal-dominant, mul- 16.1/10 000 person-years; SIR, 7.6; 95% CI, 4.0-13.2), brain (n=7; observed rate, 4.9/10 000 person-years; SIR, 5.3; 95% CI, 2.3-10.4), ovary (n=7; observed rate, 10.3/ tisystem disorder 10 000 person-years; SIR, 5.2; 95% CI, 2.3-10.2), and colon (n=10; observed rate, Mcomprising 2 subtypes.1 Type 1 MMD 7.1/10 000 person-years; SIR, 2.9; 95% CI, 1.5-5.1). Cancer risks were similar in women (Online Mendelian Inheritance in Man and men after excluding genital organ tumors (SIR, 1.9; 95% CI, 1.4-2.5, vs SIR, 1.8; [OMIM] 160900) is caused by unstable 95% CI, 1.3-2.5, respectively; P=.81 for heterogeneity; observed rates, 64.5 and 47.7 trinucleotide (CTG) repeat expansion in per 10 000 person-years in women and men, respectively). The same pattern of can- the 3Ј untranslated region of the dystro- cer excess was observed first in the Swedish and then in the Danish cohorts, which phia myotonica-protein kinase (DMPK) were studied sequentially and initially analyzed independently. gene2-4; type 2 MMD (OMIM 602668) is Conclusion Patients with MMD identified from the Swedish and Danish patient reg- a tetra-nucleotide (CCTG) repeat ex- istries were at increased risk of cancer both overall and for selected anatomic sites. pansion in intron 1 of the zinc finger 9 JAMA. 2011;306(22):2480-2486 www.jama.com (ZNF9) gene.5,6 It is the most common adult muscle dystrophy, with an esti- diac conduction defects, insulin ment, and premature cataract.1 Both mated prevalence of 1 in 8000.7 Type 1 resistance, testicular atrophy, respira- MMD subtypes result from interactions MMD displays a more severe pheno- tory insufficiency, cognitive impair- between CUG or CCUG repeat RNA and type that can present at any age (me- dian, 20-30 years)1 and result in prema- Author Affiliations: Clinical Genetics Branch (Drs of Neurology, Neuromuscular Disease Center, Uni- ture death (at 50-65 years of age).8,9 Both Gadalla, Mueller, and Greene), Biostatistics Branch (Dr versity of Rochester Medical Center, Rochester, New Pfeiffer), Infections and Immunoepidemiology Branch York (Dr Moxley and Mr Hilbert); and Division of He- subtypes share myotonia and progres- (Dr Shebl), Division of Cancer Epidemiology and Ge- matology, Department of Medicine, Karolinska Uni- sive skeletal muscle weakness and wast- netics, Medical Oncology Branch (Dr Landgren), Cen- versity Hospital Solna and Karolinska Institutet, Stock- ter for Cancer Research, Cancer Prevention Fellow- holm, Sweden (Drs Kristinsson and Bjo¨ rkholm). ing. Other manifestations include car- ship Program (Dr Gadalla), National Cancer Institute, Corresponding Author: Mark H. Greene, MD, Clini- National Institutes of Health, Bethesda, Maryland; Di- cal Genetics Branch, Division of Cancer Epidemiol- vision of Epidemiology, Department of Epidemiology ogy and Genetics, National Cancer Institute, 6120 Ex- See also Patient Page. Research, Statens Serum Institut, Denmark (Drs Lund, ecutive Blvd, EPS/7023, Rockville, MD 20892 (greenem Wohlfahrt, and Melbye and Ms Gørtz); Department @mail.nih.gov). 2480 JAMA, December 14, 2011—Vol 306, No. 22 ©2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 CANCER RISK AND MYOTONIC MUSCULAR DYSTROPHY regulatory binding proteins, mainly the Figure. Selection of Swedish and Danish Myotonic Muscular Dystrophy Patients for Inclusion muscle-blind-like (MBNL) protein fam- in the Current Study ily,10 which lead to abnormal regula- tion of pre–messenger RNA alternative Swedish Hospital Discharge Register Danish National Patient Registry 1987-2004 (inpatient 1977-2008 and outpatient 1995-2008) splicing.11 Depletion of MBNL1 in MMD has been implicated in the develop- 768 Patients with MMD discharge 1049 Patients with MMD discharge diagnosis diagnosis ment of myotonia, premature cata- 12 13,14 ract, and skin cancer. 40 Excluded 33 Excluded (died before 36 Died before start of start of follow-up) Case reports have suggested that follow-up MMD patients may be at increased risk 4 Had incomplete data of benign and malignant tumors. Pi- 728 Assessed for cancer diagnoses 1016 Assessed for cancer diagnoses lomatricoma, a rare benign calcifying cutaneous neoplasm derived from hair 59 Excluded (had cancer 27 Excluded (had cancer before start of follow-up) matrix cells, is the most commonly re- before start of follow-up) ported. Additionally, multiple skin basal 669 Included in analysis 989 Included in analysis cell carcinomas have been suggested as an MDD phenotypic variant.14-17 We Follow-up began at the date of the first myotonic muscular dystrophy (MMD)–related contact. Whereas the Swedish cohort did not capture data for patients who remained outpatients, the Danish Patient Registry cov- have previously reviewed this litera- ered all hospital admissions and outpatient visits from 1977 and 1995, respectively. ture, described neoplasms reported by participants enrolled in the National Registry of Myotonic Dystrophy and Fa- tional identification numbers, we linked the National Institutes of Health Of- cioscapulohumeral Muscular Dystro- MMD patients to the Cancer Registry. fice of Human Subjects Research be- phy and Family Members, and dis- The Swedish MMD cohort did not cap- cause all analyses were performed using cussed possible molecular reasons for ture data for patients who were man- deidentified data. a hypothetical cancer predisposi- aged exclusively as outpatients. When tion.13 analyses in Swedish MMD patients sug- Cancer Ascertainment To further explore whether the MMD gested a possible excess cancer risk, we The Swedish and Danish cancer regis- phenotype includes cancer risk, we con- sought to replicate our findings in a tries have identified all incident can- ducted a population-based linkage separate, independent population (the cers detected in Sweden and Denmark study of MMD patients using the na- Danish cohort). since 1958 and 1943, respectively. Reg- tionwide Swedish and Danish regis- The Danish National Patient Regis- istry completeness and diagnostic ac- tries. Our data provide the first objec- try covers all hospital admissions and curacy exceeded 95% in several vali- tive, quantitative evidence to suggest outpatient visits since 1977 and 1995, dation studies.21-24 For this study, cancer that the MMD syndrome includes can- respectively. All Danish registry diag- sites were identified using ICD-7 and cer susceptibility. noses are coded according to the ICD ICD-10 codes from Sweden and Den- revision 8 (1969-1993) and revision 10 mark, respectively. To ensure compa- METHODS (from 1994).20 Each individual’s unique rability between reported cancer sites, Within the Swedish Hospital Dis- civil registration number was used to we used a slightly modified version of charge Register, which began in 1964 link the patients to the Danish Cancer the NORDCAN cancer dictionary,25 and reached 100% nationwide hospi- Registry. After excluding registrants which was designed by the Associa- talization coverage in 1987, we identi- with prior cancer and those who died tion of the Nordic Cancer Registries and fied all patients with an MMD dis- prior to follow-up initiation, we iden- the International Agency for Research charge diagnosis (ICD-9 code 359C, tified 989 inpatients or outpatients dis- on Cancer to formalize Nordic coun- ICD-10 code G711) between January charged with an MMD diagnosis be- tries’ data harmonization. Amend- 1987 and December 2004 (n=768) tween 1977 and 2008 (ICD-8 codes ments to the cancer codes were made (FIGURE). Diagnoses were coded using 330.90, 330.91; ICD-10 code G711) for cancers of the brain (only malig- the International Classification of Dis- (Figure). nant tumors were included), as well as eases (ICD) revision 7 (1964-1968), re- Access to the Swedish and Danish lymphoma and leukemia, to accommo- vision 8 (1969-1986), revision 9 (1987- registry data was approved by the Karo- date differing coding schemes over time 1995), and revision 10 (after 1995).18,19 linska Institutional Review Board and in Denmark and Sweden, respec- We excluded 99 patients from analy- the Danish Data Protection Agency, re- tively.
Load more

Recommended publications
  • The Myotonic Dystrophies: Diagnosis and Management Chris Turner,1 David Hilton-Jones2
    Review J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2008.158261 on 22 February 2010. Downloaded from The myotonic dystrophies: diagnosis and management Chris Turner,1 David Hilton-Jones2 1Department of Neurology, ABSTRACT asymptomatic relatives as well as prenatal and National Hospital for Neurology There are currently two clinically and molecularly defined preimplantation diagnosis can also be performed.7 and Neurosurgery, London, UK 2Department of Clinical forms of myotonic dystrophy: (1) myotonic dystrophy Neurology, The Radcliffe type 1 (DM1), also known as ‘Steinert’s disease’; and Anticipation Infirmary, Oxford, UK (2) myotonic dystrophy type 2 (DM2), also known as DMPK alleles greater than 37 CTG repeats in length proximal myotonic myopathy. DM1 and DM2 are are unstable and may expand in length during meiosis Correspondence to progressive multisystem genetic disorders with several and mitosis. Children of a parent with DM1 may Dr C Turner, Department of Neurology, National Hospital for clinical and genetic features in common. DM1 is the most inherit repeat lengths considerably longer than those Neurology and Neurosurgery, common form of adult onset muscular dystrophy whereas present in the transmitting parent. This phenomenon Queen Square, London WC1N DM2 tends to have a milder phenotype with later onset of causes ‘anticipation’, which is the occurrence of 3BG, UK; symptoms and is rarer than DM1. This review will focus increasing disease severity and decreasing age of onset [email protected] on the clinical features, diagnosis and management of in successive generations. The presence of a larger Received 1 December 2008 DM1 and DM2 and will briefly discuss the recent repeat leads to earlier onset and more severe disease Accepted 18 December 2008 advances in the understanding of the molecular and causes the more severe phenotype of ‘congenital’ pathogenesis of these diseases with particular reference DM1 (figure 2).8 9 A child with congenital DM 1 to new treatments using gene therapy.
    [Show full text]
  • Consensus-Based Care Recommendations for Adults with Myotonic Dystrophy Type 1
    Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1 I Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1 Due to the multisystemic nature of this disease, the studies and rigorous evidence needed to drive the creation of an evidence-based guideline for the clinical care of adult myotonic dystrophy type 1 (DM1) patients are not currently available for all affected body systems and symptoms. In order to improve and standardize care for this disorder now, more than 65 leading myotonic dystrophy (DM) clinicians in Western Europe, the UK, Canada and the US joined in a process started in Spring 2015 and concluded in Spring 2017 to create the Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1. The project was organized and supported by the Myotonic Dystrophy Foundation (MDF). A complete list of authors and an overview of the process is available in Addendum 1. A complete reading list for each of the study area sections is available in Addendum 2. An Update Policy has been adopted for this document and will direct a systematic review of literature and appropriate follow up every three years. Myotonic Dystrophy Foundation staff will provide logistical and staff support for the update process. A Quick Reference Guide extrapolated from the Consensus-based Care Recommendations is available here http://www.myotonic.org/clinical-resources For more information, visit myotonic.org. Myotonic Dystrophy Foundation 1 www.myotonic.org Table of Contents Life-threatening symptoms
    [Show full text]
  • Congenital Muscular Dystrophy with Characteristic Radiological Findings Similar to Those with Fukuyama Congenital Muscular Dystrophy
    Case Report Congenital muscular dystrophy with characteristic radiological findings similar to those with Fukuyama congenital muscular dystrophy Ajay Garg, Sheffali Gulati*, Vipul Gupta, Veena Kalra* Departments of Neuroradiology and *Pediatrics, AIIMS, New Delhi, India. Fukuyama congenital muscular dystrophy (FCMD) is the quired social smile at 2 months, partial head control at 8 months, started sitting with support at 9 months and sitting without support most common congenital muscular dystrophy in Japan and at 18 months. He had no seizures. On examination, he had head lag there are isolated reports of non-Japanese patients with and hypotonia. Power was 3/5 in all limbs. Deep tendon jerks were FCMD. We report an Indian patient with congenital muscu- not elicitable. There was no muscle hypertrophy. The ophthalmic lar dystrophy and characteristic radiological findings similar examination, visual evoked potentials, motor nerve conduction stud- to those with FCMD. ies and EEG were normal. Electromyography showed a myopathic pattern. Serum creatine kinase was elevated at 2970 U/l (normal Key Words: Fukuyama congenital muscular dystrophy, con- 24-190 U/l). genital muscular dystrophy Cranial MRI revealed disorganized cerebellar folia with multiple cysts within vermis and cerebellar hemispheres (Figures 1a and 1b). There was marked pontine, and inferior vermian hypoplasia and fused midbrain colliculi (Figure 2a). The frontal lobes had shallow sulci Introduction and a bizarre pattern of the sulci parallel to each other without per- pendicular sulci (Figures 2a and 2b). There was ventriculomegaly and abnormal increased signal in periventricular white matter. The Congenital muscular dystrophy (CMD) is a heterogeneous corpus callosum had a bizarre configuration, though was not hypo- group of disorders characterized by muscular hypotonia of plastic.
    [Show full text]
  • AMERICAN ACADEMY of PEDIATRICS Cardiovascular
    AMERICAN ACADEMY OF PEDIATRICS CLINICAL REPORT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of All Children Section on Cardiology and Cardiac Surgery Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular Dystrophy ABSTRACT. Duchenne muscular dystrophy is the most ease is characterized by alternating areas of myocyte common and severe form of the childhood muscular hypertrophy, atrophy, and fibrosis.8 dystrophies. The disease is typically diagnosed between Over the last 20 years, respiratory care of this 3 and 7 years of age and follows a predictable clinical group of patients has improved as a result of the course marked by progressive skeletal muscle weakness development of supportive equipment and tech- with loss of ambulation by 12 years of age. Death occurs 9 in early adulthood secondary to respiratory or cardiac niques. Consequently, dilated cardiomyopathy is 10–12 failure. Becker muscular dystrophy is less common and increasing as the major cause of death. The time has a milder clinical course but also results in respiratory course for the development of cardiomyopathy has and cardiac failure. The natural history of the cardiomy- not been well characterized; however, clinical studies opathy in these diseases has not been well established. demonstrate that the disease process in the heart is As a result, patients traditionally present for cardiac eval- underway long before symptoms appear.13–15 Early uation only after clinical symptoms become evident. The manifestations of heart failure often go unrecognized purpose of this policy statement is to provide recommen- secondary to physical inactivity and a lack of classic dations for optimal cardiovascular evaluation to health 16 care specialists caring for individuals in whom the diag- signs and symptoms.
    [Show full text]
  • Muscular Dystrophies: What the Radiologist Should Know
    Muscular Dystrophies: What the radiologist should know J. Carmen Timberlake, MD; Kristina Siddall, MD; Christopher Bang, DO; Marat Bakman, MD; Gwy Suk Seo, MD; Johnny UV Monu, MD Department of Imaging Sciences University of Rochester Medical Center, Rochester, NY Presentation material is for education purposes only. All rights reserved. ©2006 URMC Radiology Page 1 of 39 Muscular Dystrophies: Introduction •! The muscular dystrophies are –! a group of inherited, progressive muscle disorders –! caused by mutations in genes encoding proteins required for normal muscle function. •! Biopsy reveals fiber degeneration –! this manifests clinically as weakness. Presentation material is for education purposes only. All rights reserved. ©2006 URMC Radiology Page 2 of 39 Muscular Dystrophies: Introduction •! Role of imaging in diagnosis and management –! Historically, diagnosis and evaluation of disease progression depend on clinical, pathologic, and biochemical parameters. –! Imaging has not been used for primary diagnosis or for routine follow-up evaluation. –! MRI, however, has a potential role in the work up, management, and study of muscular dystrophies Presentation material is for education purposes only. All rights reserved. ©2006 URMC Radiology Page 3 of 39 Muscular Dystrophies: Introduction Teaching points: 1.! Review of spectrum of muscular dystrophies. 2.! Review patterns of inheritance, pathophysiology of disease, clinical manifestations, and clinical management. 3.! Review radiologic findings in muscular dystrophies, with emphasis on
    [Show full text]
  • PDF-Document
    Table S1.Summary of muscular dystrophies, pathology and treatments. Mutation and/or related Type of dystrophy Affected Protein(s) Features Treatments/Therapies Reference genes No treatments are currently available that fundamentally alter the course of MMD1 or MMD2. The management of MMD patients is based on genetic Expansion of a A dominant disorder associated counseling and the preservation trinucleotide (CTG) with clinical myotonia, of social independence and repeat on chromosome progressive muscular weakness, cardiopulmonary complications Myotonic muscular Myotonic dystrophy 19q13.3 for type 1 and and extra muscular by providing symptomatic (9, 15) dystrophy (MMD) protein kinase tetranucleotide (CCTG) manifestations such as cardiac treatment for myotonia, repeats on chromosome arrhythmia and endocrine hypersomnolence, and pain. 3q21.3 for type 2 disease. dysfunction. Moreover, some experimental therapeutic approaches are under investigation, as antisense oligonucleotides (ASOs), gene therapy vectors, and small molecules. Deletions within the D4Z4 repeat region Facioscapulohumeral muscular There are no registered therapies located on chromosome dystrophy has a characteristic approved for FSHD. Although 4q35 for type 1; descending pattern of weakness, many drugs have been tested in mutations of SMCHD1 a toxic-gain-of- first affecting the face and clinical trials (prednisone Facioscapulohumeral on chromosome 18p11 in (43, 44, function DUX4 shoulder followed by the distal diltiazem, albuterol, and a dystrophy (FSHD) association with a 47) protein’ lower extremity and the myostatin inhibitor), none showed permission chromosome proximal hip girdle muscles, but a clear benefit. Stretching and 4 allele account for the many variations in the range of motion exercises are also majority of type 2 presentation can occur.
    [Show full text]
  • Cost of Amyotrophic Lateral Sclerosis, Muscular Dystrophy, and Spinal Muscular Atrophy in the United States
    HEALTHCARE AND HUMAN SERVICES POLICY, RESEARCH, AND CONSULTING ― WITH REAL-WORLD PERSPECTIVE. Cost of Amyotrophic Lateral Sclerosis, Muscular Dystrophy, and Spinal Muscular Atrophy in the United States Final Report Prepared for: Muscular Dystrophy Association Submitted by: The Lewin Group, Inc. March 1, 2012 Final Report MDA Cost of Illness in the United States Table of Contents TABLE OF EXHIBITS ..............................................................................................................................ii ABBREVIATIONS .................................................................................................................................. iii EXECUTIVE SUMMARY ........................................................................................................................ 1 1. BACKGROUND ................................................................................................................................. 4 1.1 Amyotrophic Lateral Sclerosis (ALS) ........................................................................................... 5 1.2 Muscular Dystrophy (MD) ............................................................................................................. 5 1.3 Spinal Muscular Atrophy (SMA) .................................................................................................. 7 2. METHODS .......................................................................................................................................... 8 2.1 Estimating Direct Medical Cost
    [Show full text]
  • Myofiber Branching Rather Than Myofiber Hyperplasia Contributes to Muscle Hypertrophy in Mdx Mice Faber Et Al
    Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice Faber et al. Faber et al. Skeletal Muscle 2014, 4:10 http://www.skeletalmusclejournal.com/content/4/1/10 Faber et al. Skeletal Muscle 2014, 4:10 http://www.skeletalmusclejournal.com/content/4/1/10 RESEARCH Open Access Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice Rachel M Faber1, John K Hall1, Jeffrey S Chamberlain1,2,3 and Glen B Banks1* Abstract Background: Muscle hypertrophy in the mdx mouse model of Duchenne muscular dystrophy (DMD) can partially compensate for the loss of dystrophin by maintaining peak force production. Histopathology examination of the hypertrophic muscles suggests the hypertrophy primarily results from the addition of myofibers, and is accompanied by motor axon branching. However, it is unclear whether an increased number of innervated myofibers (myofiber hyperplasia) contribute to muscle hypertrophy in the mdx mice. Methods: To better understand the cellular mechanisms of muscle hypertrophy in mdx mice, we directly compared the temporal progression of the dystrophic pathology in the extensor digitorum longus (EDL) muscle to myofiber number, myofiber branching, and innervation, from 3 to 20 weeks of age. Results: We found that a 28% increase in the number of fibers in transverse sections of muscle correlated with a 31% increase in myofiber branching. Notably, the largest increases in myofiber number and myofiber branching occurred after 12 weeks of age when the proportion of myofibers with central nuclei had stabilized and the mdx mouse had reached maturity. The dystrophic pathology coincided with profound changes to innervation of the muscles that included temporary denervation of necrotic fibers, fragmentation of synapses, and ultra-terminal axon sprouting.
    [Show full text]
  • Possible Neurogenic Factor in Muscular Dystrophy: Its Similarity to Denervation Atrophy'
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.36.3.399 on 1 June 1973. Downloaded from Joutrnal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 399-410 Possible neurogenic factor in muscular dystrophy: its similarity to denervation atrophy' DARAB K. DASTUR AND ZOHRA A. RAZZAK From the Neuropathology Unit, Postgraduate Resear ch Laboratories, Grant Medical College and J.J. Group of Hospitals, Bonzbay-8, India SUMMARY Muscle biopsy specimens from 179 cases of muscular dystrophies and from 140 cases of anterior horn cell disorders (from a total of 1,348 biopsied patients) were examined histologically. There were 72 cases of Duchenne type muscular dystrophy (DMD), five of Becker type MD, four girls with myopathy resembling DMD, 40 with limb-girdle, 10 with facioscapulohumeral, seven with late onset, 13 with congenital, and 28 with unclassifiable muscular dystrophies. Groups of small atrophied muscle fibres were encountered in 42 (23%) of the cases in this group, most frequently in patients with limb-girdle, facioscapulohumeral, and least frequently with DM dystrophy. In the second group there were 25 cases of infantile, 38 ofjuvenile, and 39 of adult spinal muscular atrophy (SMA); there were 21 patients with motor neurone disease six with and 11 (MND), poliomyelitis, Protected by copyright. with an unclassifiable type of anterior horn cell disorder. Pseudomyopathic changes were encoun- tered in 43 (300%) of all cases in this group. They were most frequently present among patients with juvenile and adult SMA and in those with MND. The presence of group atrophy in muscular dys- trophy is considered significant myopathological evidence of a denervation process.
    [Show full text]
  • MUSCULAR DYSTROPHY Date of Publication: Dec
    Disease/Medical Condition MUSCULAR DYSTROPHY Date of Publication: Dec. 20, 2017 (also known as “MD”; includes “Duchenne muscular dystrophy” [DMD], “Becker muscular dystrophy” [BMD], “oculopharyngeal muscular dystrophy [OPMD], “fascioscapulohumeral muscular dystrophy” [FSHMD]1, “limb-girdle muscular dystrophy” [LGMD], “myotonic dystrophy” [DM]2, “Emery-Dreifuss muscular dystrophy” [EDMD], and congenital muscular dystrophy [CMD]3) Note: Unless otherwise specified, this fact sheet primarily addresses the two most common types of muscular dystrophy; namely, Duchenne and Becker type. Is the initiation of non-invasive dental hygiene procedures* contra-indicated? No. Is medical consult advised? No, assuming patient/client is already under medical care for muscular dystrophy. Is the initiation of invasive dental hygiene procedures contra-indicated?** Possibly, but not typically. Is medical consult advised? ........................................See above. Is medical clearance required? Yes, if patient/client is being treated with medications associated with immunosuppression +/- increased risk of infection (i.e., corticosteroids, such as deflazacort or prednisone, which are used to preserve muscle strength in Duchenne and some other forms of muscular dystrophy), or if general anesthetic agents are contemplated (due to elevated risk of adverse reactions, some of which may be life-threatening)4, or if bisphosphonate-related osteonecrosis of the jaw (BRONJ) exists or is suspected5. Is antibiotic prophylaxis required? ................................No,
    [Show full text]
  • Congenital Muscular Dystrophy: from Muscle to Brain Raffaele Falsaperla1, Andrea D
    Falsaperla et al. Italian Journal of Pediatrics (2016) 42:78 DOI 10.1186/s13052-016-0289-9 REVIEW Open Access Congenital muscular dystrophy: from muscle to brain Raffaele Falsaperla1, Andrea D. Praticò2,3, Martino Ruggieri2, Enrico Parano4, Renata Rizzo2, Giovanni Corsello5, Giovanna Vitaliti1 and Piero Pavone1* Abstract Congenital muscular dystrophies (CMDs) are a wide group of muscular disorders that manifest with very early onset of muscular weakness, sometime associated to severe brain involvement. The histologic pattern of muscle anomalies is typical of dystrophic lesions but quite variable depending on the different stages and on the severity of the disorder. Recent classification of CMDs have been reported most of which based on the combination of clinical, biochemical, molecular and genetic findings, but genotype/phenotype correlation are in constant progression due to more diffuse utilization of the molecular analysis. In this article, the Authors report on CMDs belonging to the group of dystroglycanopathies and in particular on the most severe forms represented by the Fukuyama CMD, Muscle-Eye-Brain disease and Walker Walburg syndrome. Clinical diagnosis of infantile hypotonia is particularly difficult considering the different etiologic factors causing the lesions, the difficulty in localizing the involved CNS area (central vs. peripheral) and the limited role of the diagnostic procedures at this early age. The diagnostic evaluation is not easy mainly in differentiating the various types of CMDs, and represents a challenge for
    [Show full text]
  • Goltz Syndrome): the First Dental Case Report
    PEDIATRICDENTISTRY/Copyright © 1986 by The AmericanAcaciemy of Pediatric Dentistry Volume 8 Number 3 Focal dermal hypoplasia syndrome (Goltz syndrome): the first dental case report Steven D. Ureles, DMD,MS Howard L. Needleman, DMD Abstract In 1970 Goltz suggested that FDHSis an inherited The first dental case report of a patient with focal dermal disease since 5 of 33 reported cases of FDHShad hypoplasiasyndrome (FDHS) is presented. A review of signs and relatives with anomalies associated with the syn- symptomsof FDHSis presented along with newlyreported oral drome.2 findings. This patient apparentlyis the first personwith FDHSto The most favored genetic hypothesis is that FDHS have an absent sternumand the fifteenth personreported with is caused by an X-linked dominant gene of variable confirmedosteopathia striata. expressivity with a pronounced lethality in Cariouslesions can be difficult to restore in FDHSdue to a 2,3,6,7-t° severe enamelhypoplasia and large pulp horns associated with males. Alternately, an X-linked autosomal this syndrome.Orofacial swellings in FDHScan be either odon- translocation or environmental teratogen might be togenicin originor relatedto an infectedskin lesion as presented responsible. 11 To date, karyotype examinations have in this casereport. provided4,12 no indication of chromosomealterations. The first case reports in the literature of what ap- pear to be FDHSwere reported by Jessner in 1921 Focal dermal hypoplasia syndrome (FDHS), also and 1928.13,14 The first patient, however, who was his- known as Goltz syndrome, is a rare congenital me- tologically confirmed to have what is now known as soectodermal disorder which was first described in FDHSwas reported by Lieberman in 193525 He de- 1962.
    [Show full text]